CHRS Coherus BioSciences, Inc.

18.75
+0  (1%)
Previous Close 18.65
Open 18.75
Price To book 41.63
Market Cap 959.01M
Shares 51,147,000
Volume 524,167
Short Ratio 7.63
Av. Daily Volume 504,206

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due 1H 2017.
CHS-1420
Psoriasis
PDUFA date June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. ETFs with exposure to Coherus BioSciences, Inc. : April 5, 2017
  2. Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
  3. Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  4. Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  5. Edited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT
  6. Coherus BioSciences reports 4Q loss
  7. Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
  8. Coherus Addresses Trade Secret Action Filed by Amgen
  9. Statement by Coherus CEO Regarding Biosimilars User Fees
  10. 5 Small-Cap Biotech Stocks to Buy in March
  11. Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
  12. Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
  13. Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
  14. Coherus BioSciences Announces New Employment Inducement Grants
  15. Why Coherus Biosciences Is Falling Today
  16. Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback
  17. Coherus Prices Public Offering of Common Stock
  18. Coherus Announces Proposed Public Offering of Common Stock
  19. Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619
  20. Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : January 27, 2017